Human mast cells decrease SLPI levels in type II – like alveolar cell model, in vitro

Cancer Cell International

Ulla Westin³  Sabina Janciauskiene¹  Max Nyström⁴  Camilla Hollander² 

[1] Department of Medicine, University of Lund, SE-205 02 Malmö, Sweden;Department of Otolaryngology and Head and Neck Surgery, University of Lund, SE-205 02 Malmö, Sweden;Department of Surgical Pathophysiology, University of Lund, SE-205 02 Malmö, Sweden;Department of Surgery, University of Lund, SE-205 02 Malmö, Sweden

关键词: migration;    inflammation;    mast cells;    SLPI;   

Others  :  796071
DOI  :  10.1186/1475-2867-3-14

 received in 2003-03-10, accepted in 2003-08-20,  发布年份 2003

【 摘 要 】

Background

Mast cells are known to accumulate at sites of inflammation and upon activation to release their granule content, e.g. histamine, cytokines and proteases. The secretory leukocyte protease inhibitor (SLPI) is produced in the respiratory mucous and plays a role in regulating the activity of the proteases.

Result

We have used the HMC-1 cell line as a model for human mast cells to investigate their effect on SLPI expression and its levels in cell co-culture experiments, in vitro. In comparison with controls, we found a significant reduction in SLPI levels (by 2.35-fold, p < 0.01) in a SLPI-producing, type II-like alveolar cell line, (A549) when co-cultured with HMC-1 cells, but not in an HMC-1-conditioned medium, for 96 hours. By contrast, increased SLPI mRNA expression (by 1.58-fold, p < 0.05) was found under the same experimental conditions. Immunohistochemical analysis revealed mast cell transmigration in co-culture with SLPI-producing A549 cells for 72 and 96 hours.

Conclusion

These results indicate that SLPI-producing cells may assist mast cell migration and that the regulation of SLPI release and/or consumption by mast cells requires interaction between these cell types. Therefore, a "local relationship" between mast cells and airway epithelial cells might be an important step in the inflammatory response.

【 授权许可】

   
2003 Hollander et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Janoff A: Proteases and lung injury. A state-of-the-art minireview. Chest 1983, 83:54S-58S.
• [2]Janoff A: Elastase in tissue injury. Annu Rev Med 1985, 36:207-16.
• [3]Ohbayashi H: Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 2002, 3:409-21.
• [4]Tetley TD: Macrophages and the pathogenesis of COPD. Chest 2002, 121:156S-159S.
• [5]Finlay GA, Russell KJ, McMahon KJ, D'Arcy M, Masterson EJB, FitzGerald MX, O'Connor CM: Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax 1997, 52:502-6.
• [6]Carrell RW, Jeppsson JO, Laurell CB, Brennan SO, Owen MC, Vaughan L, Boswell DR: Structure and variation of human alpha 1-antitrypsin. Nature 1982, 298:329-34.
• [7]Fryksmark U, Ohlsson K, Polling A, Tegner H: Distribution of antileukoprotease in upper respiratory mucosa. Ann Otol Rhinol Laryngol 1982, 91:268-71.
• [8]Mooren HW, Kramps JA, Franken C, Meijer CJ, Dijkman JA: Localisation of a low-molecular-weight bronchial protease inhibitor in the peripheral human lung. Thorax 1983, 38:180-3.
• [9]Ohlsson M, Fryksmark U, Polling A, Tegner H, Ohlsson K: Localization of antileukoprotease in the parotid and the submandibular salivary glands. Acta Otolaryngol 1984, 98:147-51.
• [10]Kuijpers AL, Alkemade HA, Schalkwijk J, van de Kerkhof PC: Topographic relation between skin-derived antileukoproteinase (SKALP) and leukocyte elastase in a case of annular pustular psoriasis. Acta Derm Venereol 1995, 75:110-3.
• [11]Mihaila A, Tremblay GM: Human alveolar macrophages express elafin and secretory leukocyte protease inhibitor. Z Naturforsch [C] 2001, 56:291-7.
• [12]Saitoh H, Masuda T, Shimura S, Fushimi T, Shirato K: Secretion and gene expression of secretory leukocyte protease inhibitor by human airway submucosal glands. Am J Physiol Lung Cell Mol Physiol 2001, 280:L79-87.
• [13]Ohlsson K, Tegner H: Inhibition of elastase from granulocytes by the low molecular weight bronchial protease inhibitor. Scand J Clin Lab Invest 1976, 36:437-45.
• [14]Ohlsson K, Bjartell A, Lilja H: Secretory leucocyte protease inhibitor in the male genital tract: PSA-induced proteolytic processing in human semen and tissue localization. J Androl 1995, 16:64-74.
• [15]Tegner H: Quantitation of human granulocyte protease inhibitors in non-purulent bronchial lavage fluids. Acta Otolaryngol 1978, 85:282-9.
• [16]Fritz H: Human mucus proteinase inhibitor (human MPI). Human seminal inhibitor I (HUSI-I), antileukoprotease (ALP), secretory leukocyte protease inhibitor (SLPI). Biol Chem Hoppe Seyler 1988, 369(Suppl):79-82.
• [17]Thompson RC, Ohlsson K: Isolation, properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase. Proc Natl Acad Sci U S A 1986, 83:6692-6.
• [18]Hochstrasser K, Reichert R, Schwarz S, Werle E: [Isolation and characterisation of a protease inhibitor from human bronchial secretion]. Hoppe Seylers Z Physiol Chem 1972, 353:221-6.
• [19]Eisenberg SP, Hale KK, Heimdal P, Thompson RC: Location of the protease-inhibitory region of secretory leukocyte protease inhibitor. J Biol Chem 1990, 265:7976-81.
• [20]Renesto P, Balloy V, Kamimura T, Masuda K, Imaizumi A, Chignard M: Inhibition by recombinant SLPI and half-SLPI (Asn55-Ala107) of elastase and cathepsin G activities: consequence for neutrophil-platelet cooperation. Br J Pharmacol 1993, 108:1100-6.
• [21]Masuda K, Kamimura T, Kanesaki M, Ishii K, Imaizumi A, Sugiyama T, Suzuki Y, Ohtsuka E: Efficient production of the C-terminal domain of secretory leukoprotease inhibitor as a thrombin-cleavable fusion protein in Escherichia coli. Protein Eng 1996, 9:101-6.
• [22]Pemberton AD, Huntley JF, Miller HR: Differential inhibition of mast cell chymases by secretory leukocyte protease inhibitor. Biochim Biophys Acta 1998, 1379:29-34.
• [23]Shugars DC, Sauls DL, Weinberg JB: Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type I. Oral Dis 1997, 3(Suppl 1):S70-2.
• [24]Tomee JF, Koeter GH, Hiemstra PS, Kauffman HF: Secretory leukoprotease inhibitor: a native antimicrobial protein presenting a new therapeutic option? Thorax 1998, 53:114-6.
• [25]Jin FY, Nathan C, Radzioch D, Ding A: Secretory leukocyte protease inhibitor: a macrophage product induced by and antagonistic to bacterial lipopolysaccharide. Cell 1997, 88:417-26.
• [26]Jin F, Nathan CF, Radzioch D, Ding A: Lipopolysaccharide-related stimuli induce expression of the secretory leukocyte protease inhibitor, a macrophage-derived lipopolysaccharide inhibitor. Infect Immun 1998, 66:2447-52.
• [27]Zang Y, De Witt DL, McNeely TB, Wahl SM, Wahl LM: Secretory leukocyte protease inhibitor suppresses the production of monocyte prostaglandin H synthase-2, prostaglandin E2, and matrix metalloproteases. J Clin Invest 1997, 99:894-900.
• [28]Lentsch AB, Jordan JA, Czermak BJ, Diehl KM, Younkin EM, Sarma V, Ward PA: Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation. Am J Pathol 1999, 154:239-47.
• [29]Ward PA, Lentsch AB: Endogenous regulation of the acute inflammatory response. Mol Cell Biochem 2002, 234–235:225-8.
• [30]Ashcroft GS, Lei K, Jin W, Longenecker G, Kulkarni AB, Greenwell-Wild T, Hale-Donze H, McGrady G, Song XY, Wahl SM: Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat Med 2000, 6:1147-53.
• [31]Bruch M, Bieth JG: Influence of elastin on the inhibition of leucocyte elastase by alpha 1-proteinase inhibitor and bronchial inhibitor. Potent inhibition of elastin-bound elastase by bronchial inhibitor. Biochem J 1986, 238:269-73.
• [32]Ohlsson K: Interactions between granulocyte proteases and protease inhibitors in the lung. Bull Eur Physiopathol Respir 1980, 16:209-22.
• [33]Abbinante-Nissen JM, Simpson LG, Leikauf GD: Neutrophil elastase increases secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am J Physiol 1993, 265:L286-92.
• [34]Sallenave JM, Shulmann J, Crossley J, Jordana M, Gauldie J: Regulation of secretory leukocyte proteinase inhibitor (SLPI) and elastase-specific inhibitor (ESI/elafin) in human airway epithelial cells by cytokines and neutrophilic enzymes. Am J Respir Cell Mol Biol 1994, 11:733-41.
• [35]Grobmyer SR, Barie PS, Nathan CF, Fuortes M, Lin E, Lowry SF, Wright CD, Weyant MJ, Hydo L, Reeves F, Shiloh MU, Ding A: Secretory leukocyte protease inhibitor, an inhibitor of neutrophil activation, is elevated in serum in human sepsis and experimental endotoxemia. Crit Care Med 2000, 28:1276-82.
• [36]Abbinante-Nissen JM, Simpson LG, Leikauf GD: Corticosteroids increase secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. Am J Physiol 1995, 268:L601-6.
• [37]van Wetering S, van der Linden AC, van Sterkenburg MA, de Boer WI, Kuijpers AL, Schalkwijk J, Hiemstra PS: Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins. Am J Physiol Lung Cell Mol Physiol 2000, 278:L51-8.
• [38]Ochnio JJ, Abboud RT, Lam S, Johal SS, Smith CJ, Johnson DA: Bronchial leukocyte proteinase inhibitor levels in bronchial washings in asthma patients. Chest 1988, 93:1008-12.
• [39]Westin U, Lundberg E, Wihl JA, Ohlsson K: The effect of immediate-hypersensitivity reactions on the level of SLPI, granulocyte elastase, alpha1-antitrypsin, and albumin in nasal secretions, by the method of unilateral antigen challenge. Allergy 1999, 54:857-64.
• [40]Krishnaswamy G, Kelley J, Johnson D, Youngberg G, Stone W, Huang SK, Bieber J, Chi DS: The human mast cell: functions in physiology and disease. Front Biosci 2001, 6:D1109-27.
• [41]Bradding P, Holgate ST: The mast cell as a source of cytokines in asthma. Ann N Y Acad Sci 1996, 796:272-81.
• [42]Bradding P, Holgate ST: Immunopathology and human mast cell cytokines. Crit Rev Oncol Hematol 1999, 31:119-33.
• [43]Anderson DF, Zhang S, Bradding P, McGill JI, Holgate ST, Roche WR: The relative contribution of mast cell subsets to conjunctival TH2-like cytokines. Invest Ophthalmol Vis Sci 2001, 42:995-1001.
• [44]Church MK, Cauldfield JP: Mast cells and basophil functions. In Allery. Edited by Holgate ST, Church MK. Gover Medical Publishing; 1993:5.1-5.12.
• [45]Dietze SC, Sommerhoff CP, Fritz H: Inhibition of histamine release from human mast cells ex vivo by natural and synthetic chymase inhibitors. Biol Chem Hoppe Seyler 1990, 371(Suppl):75-9.
• [46]Westin U, Lundberg E, Ohlsson K: IgE-mediated histamine release from nasal mucosa is inhibited by SLPI (secretory leukocyte protease inhibitor) to the level of spontaneous release. Mediators Inflamm 1998, 7:217-20.
• [47]Westin U, Polling A, Ljungkrantz I, Ohlsson K: Identification of SLPI (secretory leukocyte protease inhibitor) in human mast cells using immunohistochemistry and in situ hybridisation. Biol Chem 1999, 380:489-93.
• [48]Hill AT, Bayley D, Stockley RA: The interrelationship of sputum inflammatory markers in patients with chronic bronchitis. Am J Respir Crit Care Med 1999, 160:893-8.
• [49]Pierce JA, Jeppsson JO, Laurell CB: alpha-1 Antitrypsin phenotypes determined by isoelectric focusing of the cysteine-antitrypsin mixed disulfide in serum. Anal Biochem 1976, 74:227-41.
• [50]Sigsgaard T, Brandslund L, Omland O, Hjort C, Lund ED, Pedersen OF, MR Miller: S and Z alpha1-antitrypsin alleles are risk factors for bronchial hyperresponsiveness in young farmers: an example of gene/environment interaction. Eur Respir J 2000, 16:50-5.
• [51]Chaughey GH: The structure and airway biology of mast cell proteinases. Am J Resoir Cell Mol Biol 1991, 4:387-394.
• [52]Nilsson G, Metcalf DD: Contemporary issues in mast cell biology. Allergy and Asthma Proc 1990, 17:59-63.
• [53]Trautmann A, Feuerstein B, Ernst N, Brocker EB, Klein CE: Heterotypic cell-cell adhesion of human mast cells to fibroblasts. Arch Dermatol Res 1997, 289:194-203.
• [54]Kruger-Krasagakes S, Grutzkau A, Baghramian B, Henz BM: Interactions of immature human mast cells with extracellular matrix: expression of specific adhesion receptors and their role in cell binding to matrix proteins. J Invest Dermatol 1996, 106:538-43.
• [55]Weber S, Babina M, Feller G, Henz BM: Human leukaemic (HMC-1) and normal skin mast cells express beta 2-integrins: characterization of beta 2-integrins and ICAM-1 on HMC-1 cells. Scand J Immunol 1997, 45:471-81.
• [56]Olsson N, Piek E, ten Dijke P, Nilsson G: Human mast cell migration in response to members of the transforming growth factor-beta family. J Leukoc Biol 2000, 67:350-6.
• [57]Turner H, Kinet JP: Signalling through the high-affinity IgE receptor Fc epsilonRI. Nature 1999, 402:B24-30.
• [58]Miller HD, Pemberton AD: Tissue-specific expression of mast cell granule serine proteinases and their role in inflammation in the lung and gut. Immunology 2002, 04:375-390.
• [59]Butterfield JH, Weiler D, Dewald G, Gleich GJ: Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res 1988, 12:345-355.
• [60]Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162:156-9.